Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies

(2015) Grant S. Schulert et al.   Annual Review of Medicine

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ

(2015) Karen Put et al.   RHEUMATOLOGY

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2015) Sarah Ringold et al.   ARTHRITIS AND RHEUMATISM

Macrophage activation syndrome and cytokine-directed therapies

(2014) Grant S. Schulert et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome

(2014) Masafumi Kobayashi et al.   Modern Rheumatology

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model

(2014) Claudia Bracaglia et al.   Pediatric Rheumatology

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab

(2014) Fabrizio De Benedetti et al.   Pediatric Rheumatology

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2014) Sarah Ringold et al.   ARTHRITIS CARE & RESEARCH

Genetic Defects in Cytolysis in Macrophage Activation Syndrome

(2014) Mingce Zhang et al.   Current Rheumatology Reports

Interferon-γ Mediates Anemia but Is Dispensable for Fulminant Toll-like Receptor 9-Induced Macrophage Activation Syndrome and Hemophagocytosis in Mice

(2013) Scott W. Canna et al.   ARTHRITIS AND RHEUMATISM

Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome

(2013) P. J. KAHN et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6

(2012) Masaki Shimizu et al.   CYTOKINE

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome

(2011) Raffaele Strippoli et al.   ARTHRITIS AND RHEUMATISM

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

(2011) Nicolino Ruperto et al.   ARTHRITIS AND RHEUMATISM

Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH

(2011) K. Zhang et al.   BLOOD

An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

(2011) S. DAVI et al.   JOURNAL OF RHEUMATOLOGY

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients

(2010) P. M. Miettunen et al.   RHEUMATOLOGY

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

(2010) M. Shimizu et al.   RHEUMATOLOGY

Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin

(2009) Andreea Coca et al.   CLINICAL IMMUNOLOGY

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis

(2009) Sebastiaan J. Vastert et al.   RHEUMATOLOGY

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET